ESR1 rs1122515: Estradiol Sensitivity and Menopause Timing
The rs1122515 variant is a single nucleotide polymorphism located within the human estrogen receptor 1 (ESR1) gene. Research associates this variant with subtle shifts in physiological sensitivity to circulating estradiol and variations in the timing of natural menopause. Because current scientific evidence remains limited, it reflects modest statistical associations across studied populations rather than a deterministic outcome.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | Homozygous for the reference allele. In population research, this baseline genotype reflects typical sensitivity to circulating estradiol and average age-related menopause trajectories within studied cohorts. | Informational |
| CT | Heterozygous genotype carrying one copy of each allele. Individuals with this genotype possess an intermediate profile in association studies examining estrogen receptor signaling and menopause onset. | Informational |
| TT | Homozygous for the alternative allele. Research cohorts suggest this genotype may correlate with subtle differences in estradiol sensitivity and slight statistical variations in menopause timing, though overall clinical evidence remains limited. | Informational |
Genetic Location and Variant Details
The single nucleotide polymorphism cataloged as rs1122515 is located on human chromosome 6 within the ESR1 gene locus. As cataloged in reference genomic repositories such as dbSNP, this polymorphism involves a base substitution resulting in common genomic alleles. Like many non-coding variants identified through genome-wide research, rs1122515 is thought to exert its potential influence not by fundamentally altering the primary amino acid sequence of the estrogen receptor protein, but by potentially modulating gene expression, transcriptional efficiency, or tissue-specific mRNA splicing patterns. Reference databases like gnomAD and dbSNP document its genomic coordinates, demonstrating that it represents a common form of natural human variation rather than a rare pathogenic mutation.
The Biological Role of the ESR1 Gene
The ESR1 gene provides instructions for producing estrogen receptor alpha (ER-alpha), a ligand-activated transcription factor that plays a fundamental biological role in human reproductive endocrinology and tissue homeostasis. When circulating estrogen, predominantly 17-beta-estradiol, binds to ER-alpha, the receptor undergoes conformational activation, translocates to the cell nucleus, and binds directly to specific estrogen response elements in genomic DNA to activate or repress target genes. This pathway regulates a wide array of physiological functions across organ systems, including the maintenance of the female reproductive tract, ovarian follicle development, bone mineral density maintenance, cardiovascular vascular tone, and central nervous system signaling. Subtle alterations in ESR1 expression or sensitivity can therefore influence how target tissues interpret circulating hormonal signals across the lifespan.
Evidence on Estradiol Sensitivity and Menopause Timing
Scientific investigations recorded in public resources such as PubMed and the GWAS Catalog have evaluated variants across the ESR1 locus for associations with reproductive timeline markers, specifically the age at natural menopause and sensitivity to circulating estradiol. Epidemiological and genetic association studies note that individuals carrying certain alleles may experience modest shifts in estradiol feedback sensitivity and slight variations in the timing of reproductive cessation. However, the overall strength of evidence for rs1122515 specifically remains categorized as limited. The observed effect sizes in population cohorts are modest, and natural menopause timing is a complex, polygenic trait shaped by thousands of variants alongside environmental factors, reproductive history, and lifestyle.
Population Frequency and Distribution
The rs1122515 variant is common across human populations, with its minor allele frequency estimated at approximately 0.35 in individuals of European ancestry. Broad population sequencing projects, including data hosted by gnomAD and Ensembl, demonstrate that common variants in the ESR1 region often exhibit varying allele distributions across different continental ancestries, such as African, East Asian, and European cohorts. Because genome-wide and candidate-gene studies often feature variable ancestry representation, findings documented in one ancestral group cannot be assumed to apply uniformly to others without targeted cross-population replication.
Practical Implications and Clinical Perspective
Understanding your rs1122515 genotype provides an educational glimpse into how common genetic variations can subtly modulate hormonal biology, but it is not a diagnostic or prognostic test. A single genetic variant cannot predict the exact onset of menopause, diagnose fertility issues, or determine endocrine health. Individuals with concerns regarding perimenopause, hormonal symptoms, or hormone replacement therapies should interpret consumer genetic data with caution and consult qualified healthcare providers or pharmacists for clinical evaluations, as medical management relies on clinical symptoms, laboratory assays, and validated health guidelines rather than isolated genetic markers.
How common is this variant?
The minor allele frequency for rs1122515 is approximately 0.35 in populations of European ancestry, with common genotypes distributed across global populations as documented in reference sequencing databases.
Frequently asked questions
Can rs1122515 predict the exact age I will reach menopause?
No. The age at natural menopause is a highly polygenic trait influenced by hundreds of genetic loci together with lifestyle, nutrition, and reproductive history. Variant rs1122515 confers only a minor statistical association and cannot be used as a predictive test.
Does having the TT genotype mean I will have estrogen deficiency?
No, this genotype does not cause hormone deficiency or endocrine pathology. It is a common, natural genetic variant linked only to subtle differences in receptor sensitivity within population-level research studies.
Should this genotype influence my decisions about hormone replacement therapy?
No clinical guidelines currently support altering hormone replacement therapy based on the rs1122515 genotype. Any decisions regarding hormone therapy or medication dosing should be discussed directly with your healthcare provider or clinical pharmacist.
Why is the evidence strength for this variant described as limited?
Evidence is characterized as limited because findings are based on observational candidate or association studies that demonstrate modest effect sizes, and results have not yet established direct clinical utility or uniform effects across diverse ancestral populations.
Sources & further reading
Educational information only, last refreshed 9/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1122515?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29